Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine.
Pregenual anterior cingulate cortex (pgACC) hyperactivity differentiates treatment responders from non-responders to various pharmacological antidepressant interventions, including ketamine, an N-methyl-D-aspartate receptor antagonist. Evidence of pgACC hyperactivition during non-emotional working memory tasks in patients with major depressive disorder (MDD) highlights the importance of this region for processing both emotionally salient and cognitive stimuli. However, it is unclear whether pgACC activity might serve as a potential biomarker of antidepressant response during working memory tasks as well, in line with previous research with emotionally arousing tasks. This study tested the hypothesis that during the N-back task, a widely used working memory paradigm, low pretreatment pgACC activity, as well as coherence between the pgACC and the amygdala, would be correlated with the clinical improvement after ketamine. Magnetoencephalography (MEG) recordings were obtained from 15 drug-free patients with MDD during working memory performance 1 to 3 days before receiving a single ketamine infusion. Functional activation patterns were analyzed using advanced MEG source analysis. Source coherence analyses were conducted to quantify the degree of long-range functional connectivity between the pgACC and the amygdala. Patients who showed the least engagement of the pgACC in response to increased working memory load showed the greatest symptomatic improvement within 4 h of ketamine administration (r=0.82, p=0.0002, false discovery rate (FDR) <0.05). Pretreatment functional connectivity between the pgACC and the left amygdala was negatively correlated with antidepressant symptom change (r=-0.73, p=0.0021, FDR <0.05).These data implicate the pgACC and its putative interaction with the amygdala in predicting antidepressant response to ketamine in a working memory task context.
Salvadore
Giacomo
G
Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA. salvadoreg@mail.nih.gov
Cornwell
Brian R
BR
Sambataro
Fabio
F
Latov
David
D
Colon-Rosario
Veronica
V
Carver
Frederick
F
Holroyd
Tom
T
DiazGranados
Nancy
N
Machado-Vieira
Rodrigo
R
Grillon
Christian
C
Drevets
Wayne C
WC
Zarate
Carlos A
CA
D000328:Adult; D000679:Amygdala / Q000187:drug effects* / Q000503:physiopathology; D000928:Antidepressive Agents / Q000008:administration & dosage*; D001931:Brain Mapping; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D006179:Gyrus Cinguli / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D007649:Ketamine / Q000008:administration & dosage*; D015225:Magnetoencephalography / Q000379:methods; D008297:Male; D008570:Memory, Short-Term / Q000187:drug effects*; D008875:Middle Aged; D009434:Neural Pathways / Q000187:drug effects / Q000502:physiology; D009483:Neuropsychological Tests; D011237:Predictive Value of Tests; D011569:Psychiatric Status Rating Scales; D012189:Retrospective Studies; D013223:Statistics as Topic; D016896:Treatment Outcome
D000928:Antidepressive Agents; D007649:Ketamine
Neuroimage. 2002 Apr;15(4):870-8
11906227
Neuroimage. 2005 Jul 1;26(3):860-9
15955496
Neuroimage. 2006 Jan 1;29(1):203-15
16157491
Comput Biomed Res. 1996 Jun;29(3):162-73
8812068
Biol Psychiatry. 2009 Sep 1;66(5):522-6
19545857
Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):694-9
11209067
J Neurosci. 1991 Aug;11(8):2383-402
1869921
Am J Psychiatry. 1995 Mar;152(3):341-51
7864258
Nat Rev Neurosci. 2008 Oct;9(10):788-96
18784657
Biol Psychiatry. 2007 Dec 1;62(11):1272-80
17585888
J Clin Psychiatry. 2001;62 Suppl 16:10-7
11480879
Arch Gen Psychiatry. 2008 Feb;65(2):154-64
18250253
Am J Psychiatry. 2007 May;164(5):778-88
17475737
Psychiatry Res. 1999 Oct 11;91(3):127-39
10641577
Hum Brain Mapp. 2005 Jun;25(2):199-211
15846771
Biol Psychiatry. 2003 Mar 1;53(5):376-84
12614990
J Neurosci. 2005 Nov 9;25(45):10390-402
16280578
Arch Gen Psychiatry. 2006 Aug;63(8):856-64
16894061
Hum Brain Mapp. 2009 Sep;30(9):2746-56
19086021
Cereb Cortex. 1999 Jan-Feb;9(1):20-6
10022492
Mol Psychiatry. 2007 Feb;12(2):158-66
16983390
Arch Gen Psychiatry. 2004 Jan;61(1):34-41
14706942
Neuroimage. 2002 May;16(1):103-14
11969322
Brain Struct Funct. 2008 Sep;213(1-2):93-118
18704495
J Physiol. 2000 Feb 15;523 Pt 1:259-70
10673560
Neuropsychopharmacology. 2008 Aug;33(9):2080-92
18172433
Br J Psychiatry. 1979 Apr;134:382-9
444788
Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11747-52
19564605
Biol Psychiatry. 2007 Dec 1;62(11):1236-43
17601497
Biol Psychiatry. 2009 Feb 15;65(4):289-95
18822408
J Clin Invest. 2009 Apr;119(4):717-25
19339763
Am J Psychiatry. 2006 Jan;163(1):28-40
16390886
Neuropsychopharmacology. 2008 Jul;33(8):1909-18
17987064
Neuroreport. 1997 Mar 3;8(4):1057-61
9141092
Methods. 2001 Oct;25(2):249-71
11812209
Biol Psychiatry. 2009 Jan 15;65(2):181-4
18996507
Neuropsychopharmacology. 2005 Jul;30(7):1334-44
15856081
Psychol Methods. 2002 Mar;7(1):19-40
11928888